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This study is a prospective evaluation of the relationship
between C-reactive protein (CRP), and D-dimer (DD) and the
progression of peripheral arterial disease (PAD). The authors are
probing an important yet controversial clinical area. For the aver-
age reader, the presentation will be confusing and somewhat
bewildering, as this article has been written for those who under-
stand these types of trials and statistics. However, even the casual
reader will be able to understand the fundamental questions and
conclusions.
The authors studied 332 of 384 enrolled patients over a 7-year
period. The patients were originally part of the Homocysteine and
Progression of Atherosclerosis Study (HPAS). This trial started in
1991, and the first phase examined the relationship between the
homocysteine level and progression of PAD. The second phase of
the trial is a prospective, randomized, double-blind study examin-
ing the effects of folate vs placebo to prevent the progression of
PAD.
The current study represents a secondary set of objectives
derived from the second phase trial. The authors are presenting
data that examined the relationship between time to the variousexamined by life-table analysis and Cox proportional hazards anal-
ysis. The data showed that in subjects with symptomatic PAD,
death from a cardiovascular cause was slightly more likely in those
with elevated baseline DD and that DDwas significantly associated
with the occurrence of myocardial infarction. However, the study
did not find a relationship between progression of PAD and
baseline DD or CRP. The findings of this study appear straightfor-
ward and are very important, as several other studies have sug-
gested that DD andCRP as goodmarkers to predict progression of
PAD.
In summary, the study is extremely well designed and very well
described. The study is important for two reasons. First, the
authors have examined an important scientific and clinical question
and have provided the reader with data showing that DD and CRP
are not good markers of progression of PAD. These findings are
contrary to several previous studies and as such are somewhat
controversial. Second, this study is also important because it serves
as an excellent example of how to design a clinical trial that has far
reaching importance, yet examines very straightforward and simple
hypotheses.
